Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Cancer Tumor Profiling Global Market Opportunities and Strategies to 2035

globenewswire.com
ILMN Illumina Inc. is mentioned as a major player in the cancer tumor profiling market, which is experiencing significant growth. The company's involvement in next-generation sequencing (NGS) positions it within a dominant technology segment. TMO Thermo Fisher Scientific Inc. is identified as a major player in the growing cancer tumor profiling market. The company's broad portfolio likely benefits from the increasing adoption of precision oncology and advanced profiling solutions. QGEN QIAGEN N.V. is listed as a key company in the cancer tumor profiling market. The company's focus on diagnostics and genomics aligns with the market's growth drivers, particularly in personalized medicine.

Cancer Tumor Profiling Global Market Opportunities and Strategies to 2035 Dublin, July 14, 2026 (GLOBE NEWSWIRE) -- The "Cancer Tumor Profiling Global Market Opportunities and Strategies to 2035" has been added to ResearchAndMarkets.com's offering.

This report provides an in-depth analysis of the cancer tumor profiling market, highlighting key trends and growth forecasts from 2020 to 2035. The market's value reached approximately $14.97 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 13.1% since 2020. It is projected to expand to $26.5 billion by 2030 at a 12.1% CAGR, eventually reaching $44.74 billion by 2035 at an 11% CAGR.

Key growth drivers during the historic period included the rising global cancer incidence, increased public-private initiatives for cancer screening, growing cancer research investments, and favorable government support. However, growth was hindered by high costs, limited reimbursement, regulatory challenges, and clinical validation requirements.

In the forecast period, the adoption of precision oncology, expansion of liquid biopsy testing, and increased focus on targeted therapies will drive market growth. Potential obstacles may include policy barriers, payer skepticism, a lack of trained professionals, and impacts from trade wars and tariffs.

Prominent market trends feature liquid biopsy multi-gene panels for comprehensive genomic profiling, hybrid capture-based sequencing platforms, advanced multi-gene profiling solutions for precision oncology, and whole exome sequencing-based profiles.

The market is segmented by cancer type, technology, process type, and application. Among cancer types, breast cancer led in 2025, accounting for 26.8% of the market. Lung cancer is projected to witness the fastest growth at a 14.4% CAGR from 2025 to 2030. From a technology perspective, next-generation sequencing (NGS) dominated, capturing 36.5% of the market, with the immunohistochemistry (IHC) segment estimated to grow fastest at a 15.4% CAGR. By process type, genomics was the largest segment, representing 42.5% of the market, while epigenetics is anticipated to grow fastest at a 15.6% CAGR. In application terms, diagnostics topped the market, but personalized medicine is predicted to grow fastest at a 14.4% CAGR.

Regionally, North America was the largest market in 2025, contributing 43.6% of the total value, followed by Asia Pacific. The fastest growth is expected in Asia Pacific and North America, with CAGRs of 14.3% and 11.7%, respectively. The market remains fragmented, with major players like Illumina Inc., Thermo Fisher Scientific Inc., and F. Hoffmann-La Roche Ltd. (Foundation Medicine) leading, collectively accounting for a small market share.

Strategic opportunities lie in breast cancer, next-generation sequencing, genomics, and diagnostics applications. The USA is projected to see the largest market size gain, at $4.42 billion by 2030. To capitalize on these opportunities, the report suggests focusing on liquid biopsy-based genomic profiling, expanding hybrid capture sequencing platforms, enhancing integration of multi-gene genomic profiling, and optimizing pricing and reimbursement strategies in oncology diagnostics.

Additionally, cancer tumor profiling companies are advised to enhance stakeholder engagement, broaden distribution channels, and increase emphasis on physician-centric, evidence-based education and outreach.

Cancer Tumor Profiling Global Market Opportunities and Strategies to 2035 offers crucial insights for strategists, marketers, and senior management to evaluate the global cancer tumor profiling market as it navigates post-COVID-19 developments. Here's why you should consider acquiring this report:

The report answers critical questions such as identifying the largest and fastest-growing cancer tumor profiling markets, understanding market interrelations with the economy and similar markets, and exploring future market-shaping forces.

Key features of the report include:

Markets Covered:

Key Companies: Illumina Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Caris Life Sciences Inc., QIAGEN N.V.

Regions and Countries: Includes major regions like Asia-Pacific, North America, Europe, and countries such as USA, Canada, China, and more.

Time Series: Offers a five-year historic and a ten-year forecast overview.

Additional Data: Ratios of market size, GDP proportions, and cancer tumor profiling indicators.

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/h6688r

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.